CA2965379A1 - Carbidopa and l-dopa prodrugs and methods of use - Google Patents

Carbidopa and l-dopa prodrugs and methods of use Download PDF

Info

Publication number
CA2965379A1
CA2965379A1 CA2965379A CA2965379A CA2965379A1 CA 2965379 A1 CA2965379 A1 CA 2965379A1 CA 2965379 A CA2965379 A CA 2965379A CA 2965379 A CA2965379 A CA 2965379A CA 2965379 A1 CA2965379 A1 CA 2965379A1
Authority
CA
Canada
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
carbidopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2965379A
Other languages
English (en)
French (fr)
Inventor
Benoit Cardinal-David
Vincent S. Chan
Kassibla E. Dempah
Brian P. Enright
Rodger F. Henry
Raimundo Ho
Ye Huang
Alexander D. Huters
Russell C. Klix
Scott W. Krabbe
Philip R. Kym
Yanbin Lao
Xiaochun Lou
Sean E. MACKEY
Mark A. Matulenko
Peter T. Mayer
Christopher P. Miller
James Stambuli
Eric A. Voight
Zhi Wang
Geoff G. Zhang
Valentino J. Stella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2965379(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA2965379A1 publication Critical patent/CA2965379A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2965379A 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and methods of use Abandoned CA2965379A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
US62/066,771 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (1)

Publication Number Publication Date
CA2965379A1 true CA2965379A1 (en) 2016-04-28

Family

ID=54478240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2965379A Abandoned CA2965379A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and methods of use

Country Status (37)

Country Link
US (7) US9446059B2 (enExample)
EP (3) EP3209302B1 (enExample)
JP (6) JP6567049B2 (enExample)
KR (3) KR20240113982A (enExample)
CN (4) CN111362980B (enExample)
AR (1) AR102389A1 (enExample)
AU (4) AU2015335941B2 (enExample)
BR (1) BR112017008198B1 (enExample)
CA (1) CA2965379A1 (enExample)
CY (2) CY1121826T1 (enExample)
DK (1) DK3209302T3 (enExample)
ES (1) ES2739536T3 (enExample)
FI (1) FIC20230014I1 (enExample)
FR (1) FR23C1035I2 (enExample)
HR (1) HRP20191285T1 (enExample)
HU (2) HUE044115T2 (enExample)
IL (3) IL251829B (enExample)
LT (2) LT3209302T (enExample)
LU (1) LUC00304I2 (enExample)
MX (2) MX381069B (enExample)
MY (1) MY189519A (enExample)
NL (1) NL301224I2 (enExample)
NO (1) NO2023013I1 (enExample)
PH (1) PH12017500746B1 (enExample)
PL (1) PL3209302T3 (enExample)
PT (1) PT3209302T (enExample)
RS (1) RS58972B1 (enExample)
RU (2) RU2021103000A (enExample)
SA (1) SA521421115B1 (enExample)
SG (1) SG11201703170RA (enExample)
SI (1) SI3209302T1 (enExample)
SM (1) SMT201900376T1 (enExample)
TR (1) TR201908296T4 (enExample)
TW (2) TWI755257B (enExample)
UA (1) UA120437C2 (enExample)
WO (1) WO2016065019A1 (enExample)
ZA (1) ZA201702760B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3209302T3 (da) * 2014-10-21 2019-05-13 Abbvie Inc Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom
WO2017184871A1 (en) * 2016-04-20 2017-10-26 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
CA3028423A1 (en) * 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
US10729710B2 (en) 2017-11-24 2020-08-04 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
MY203233A (en) 2018-09-13 2024-06-19 Univ Canberra Methods of inhibition
CA3117983A1 (en) * 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US12319710B2 (en) 2019-05-21 2025-06-03 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's diseases
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) * 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
CA2309792A1 (en) * 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
KR20050027095A (ko) 2002-06-20 2005-03-17 닛폰 스이산 가부시키가이샤 프로드러그, 그 의약으로서의 사용 및 그 제법
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
CA2536175C (en) 2003-08-29 2013-05-28 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
JP2007509975A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン ギャバペンチン及びプレギャバリンの増加された吸収のための組成物及び投与形態物
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
BRPI0512970A (pt) 2004-07-06 2008-04-22 Abbott Lab prodrogas de inibidores da hiv protease
CN101365439B (zh) * 2005-12-05 2012-12-26 克塞诺波特公司 左旋多巴前体药物甲磺酸盐、其组合物及其用途
WO2007138086A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
WO2007144422A2 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
MX2010008711A (es) * 2008-02-06 2011-05-03 Wockhardt Ltd Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
AU2010250766B2 (en) 2009-05-19 2015-04-09 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
NZ610911A (en) 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
AU2011337596B2 (en) 2010-12-02 2016-07-07 Ono Pharmaceutical Co., Ltd. Novel compound and medical use thereof
AU2011341316A1 (en) 2010-12-10 2013-07-04 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
JP6472391B2 (ja) 2013-03-13 2019-02-20 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
DK3209302T3 (da) 2014-10-21 2019-05-13 Abbvie Inc Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
WO2017184871A1 (en) 2016-04-20 2017-10-26 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
US10730895B2 (en) 2020-08-04
CN107206013A (zh) 2017-09-26
NO2023013I1 (no) 2023-03-20
UA120437C2 (uk) 2019-12-10
AU2021201414A1 (en) 2021-03-25
TWI718999B (zh) 2021-02-21
RU2021103000A (ru) 2021-03-01
JP2017537066A (ja) 2017-12-14
JP2023174770A (ja) 2023-12-08
KR20170071599A (ko) 2017-06-23
JP2021183628A (ja) 2021-12-02
JP7688087B2 (ja) 2025-06-03
RU2017117413A (ru) 2018-11-26
AU2025238004A1 (en) 2025-10-16
US20220153765A1 (en) 2022-05-19
KR20230066484A (ko) 2023-05-15
TW202131931A (zh) 2021-09-01
AU2023210650A1 (en) 2023-08-24
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
SA521421115B1 (ar) 2022-03-01
IL268885A (en) 2019-10-31
US20180079762A1 (en) 2018-03-22
KR102537018B1 (ko) 2023-05-30
CN111454290A (zh) 2020-07-28
JP6750076B2 (ja) 2020-09-02
EP3209302B1 (en) 2019-04-24
LUC00304I2 (enExample) 2025-09-22
RS58972B1 (sr) 2019-08-30
EP4186510A1 (en) 2023-05-31
JP6567049B2 (ja) 2019-08-28
NL301224I2 (nl) 2023-08-16
IL251829B (en) 2019-09-26
HRP20191285T1 (hr) 2019-10-18
FR23C1035I2 (fr) 2025-04-18
JP6932227B2 (ja) 2021-09-08
CN111362980B (zh) 2022-10-18
AU2021201414B2 (en) 2023-05-11
US11091507B2 (en) 2021-08-17
RU2743347C2 (ru) 2021-02-17
NZ769153A (en) 2024-04-26
NL301224I1 (enExample) 2023-03-29
WO2016065019A1 (en) 2016-04-28
JP2019218356A (ja) 2019-12-26
IL268885B (en) 2020-08-31
HUS2300009I1 (hu) 2023-03-28
AU2015335941B2 (en) 2021-04-01
PT3209302T (pt) 2019-07-19
FIC20230014I1 (fi) 2023-03-31
LTPA2023519I1 (enExample) 2023-06-26
JP2025118978A (ja) 2025-08-13
TR201908296T4 (tr) 2019-06-21
BR112017008198B1 (pt) 2021-02-09
MY189519A (en) 2022-02-16
TW201630924A (zh) 2016-09-01
CY1121826T1 (el) 2020-07-31
AR102389A1 (es) 2017-02-22
LTC3209302I2 (enExample) 2025-10-10
JP2020189864A (ja) 2020-11-26
CY2023010I2 (el) 2023-06-09
TWI755257B (zh) 2022-02-11
MX2017005236A (es) 2017-07-26
AU2015335941A1 (en) 2017-05-04
NZ730996A (en) 2024-04-26
PH12017500746A1 (en) 2017-10-30
IL276493A (en) 2020-09-30
EP3569587A1 (en) 2019-11-20
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
PH12017500746B1 (en) 2021-12-15
PL3209302T3 (pl) 2019-10-31
US20230106081A1 (en) 2023-04-06
SMT201900376T1 (it) 2019-09-09
US20160106765A1 (en) 2016-04-21
RU2017117413A3 (enExample) 2019-05-30
MX393568B (es) 2025-03-24
IL251829A0 (en) 2017-06-29
CN111494395A (zh) 2020-08-07
CN111362980A (zh) 2020-07-03
SG11201703170RA (en) 2017-05-30
US10174061B2 (en) 2019-01-08
ZA201702760B (en) 2022-05-25
EP3209302A1 (en) 2017-08-30
CN111494395B (zh) 2024-06-21
LT3209302T (lt) 2019-06-10
US9446059B2 (en) 2016-09-20
US20160362431A1 (en) 2016-12-15
KR20240113982A (ko) 2024-07-23
SI3209302T1 (sl) 2019-06-28
DK3209302T3 (da) 2019-05-13
CN111454290B (zh) 2022-12-23
US20190375770A1 (en) 2019-12-12
US20200262852A1 (en) 2020-08-20
MX381069B (es) 2025-03-12
MX2021003840A (es) 2022-06-30
ES2739536T3 (es) 2020-01-31

Similar Documents

Publication Publication Date Title
AU2021201414B2 (en) Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease
US20240024338A1 (en) Carbidopa and l-dopa prodrugs and methods of use
HK40092679A (en) Intermediates and process for preparing l-dopa diphosphate
HK40017405A (en) Intermediates and process for preparing l-dopa diphosphate
HK40034110B (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK40034110A (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK1240507A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK1240507B (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
BR122020023057B1 (pt) Compostos de carbidopa e l-dopa, composições farmacêuticas compreendendo ditos compostos e uso das mesmas para tratar doença de parkinson ou para fornecer terapia de resgate a um indivíduo tendo doença de parkinson

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201021

EEER Examination request

Effective date: 20201021

EEER Examination request

Effective date: 20201021

EEER Examination request

Effective date: 20201021

EEER Examination request

Effective date: 20201021

FZDE Discontinued

Effective date: 20231011